Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Arch Biopartners Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Arch Biopartners Inc. market cap is $69.29M.
What is the 52-week high for Arch Biopartners Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Arch Biopartners Inc. 52 week high is $1.68 as of September 05, 2026.
What is the 52-week low for Arch Biopartners Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Arch Biopartners Inc. 52 week low is $0.39 as of September 05, 2026.
What is Arch Biopartners Inc. stock price today?
Arch Biopartners Inc. stock price today is $1.02.
What was Arch Biopartners Inc. stock price yesterday?
Arch Biopartners Inc. stock price yesterday was $1.08.
What is the PE ratio of Arch Biopartners Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Arch Biopartners Inc.'s P/E ratio is -24.06.
What is the Price-to-Book ratio of Arch Biopartners Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Arch Biopartners Inc. P/B ratio is -17.3854.
What is the 50-day moving average of Arch Biopartners Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Arch Biopartners Inc. 50-day moving average is $0.947.